Litigation over a diabetes drug that allegedly causes heart problems has reached significant milestones with the federal multidistrict litigation judge ruling that the plaintiffs’ experts pass scientific rigor and with more than 1,000 cases in Philadelphia Common Pleas Court settling for undisclosed amounts.